Shire settles with Actavis, Watson Pharma on ADHD drug

April 25 Thu Apr 25, 2013 9:51am EDT

April 25 (Reuters) - Drugmaker Shire Plc said it settled all litigation with Actavis Inc and Watson Pharma, allowing the two companies to sell a generic version of Shire's drug, Intuniv, to treat attention deficit hyperactivity disorder.

The settlement gives Actavis the license to make and sell its version of Intuniv in the United States from Dec. 1, 2014.

Actavis will get a 180-day period to exclusively market Intuniv, during which it will have to pay Shire a royalty of 25 percent of gross profits from the sale of the drug.

Watson will be allowed to make and sell its version of the drug in the United States 181 days after Actavis launches its version.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.